Douglas Bauer, MD

Professor

Dr. Bauer has been a clinician-investigator in the Division of General Internal Medicine at UCSF since 1992, where he maintains a general medicine practice (Mt Zion), teaches students, residents and junior faculty, and is active in clinical research. As an executive member of the San Francisco Coordinating Center, he direct the Endpoints and Medication Coding Groups. He currently serves as the Director of the CTSI-funded K Scholar Program which provides clinical and translational research training, mentoring and funding to promising UCSF faculty from all schools and departments. Prior to the K program he started and directed the CTSI-funded Resident Research Training Program at UCSF. His own research interests include the etiology, diagnosis and treatment of osteoporosis and other skeletal disorders, clinical biomarkers, and thyroid dysfunction. Dr. Bauer is a standing member of the NIH Neurologic, Aging, and Musculoskeletal Epidemiology (NAME) Study Section, a member of the California Technology Assessment Forum, and a Trustee for the National Osteoporosis Foundation.
Education
Residency, - School of Medicine, University of California, San Francisco
Websites
  • Home
Publications
  1. Subclinical thyroid dysfunction and depressive symptoms: protocol for a systematic review and individual participant data meta-analysis of prospective cohort studies.
  2. Clinical Use of Bone Turnover Markers.
  3. Association of Disease Definition, Comorbidity Burden, and Prognosis With Hip Fracture Probability Among Late-Life Women.
  4. Response Letter to the Editor-Diamond et al, JBMR.
  5. Radiological criteria for atypical features of femur fractures: what we can learn when applied in a clinical study setting.
  6. Glycated peptide levels are associated with cognitive decline among non-diabetic older women.
  7. Change in Bone Density and Reduction in Fracture Risk: A Meta-Regression of Published Trials.
  8. The Efficacy and Safety of Vertebral Augmentation: A Second ASBMR Task Force Report.
  9. Identifying Dormant Growth State of Mycobacteria by Orthogonal Analytical Approaches on a Single Cell and Ensemble Basis.
  10. Comparison of BMD Changes and Bone Formation Marker Levels 3 Years After Bisphosphonate Discontinuation: FLEX and HORIZON-PFT Extension I Trials.
  11. Temporal stability of urinary cadmium in samples collected several years apart in a population of older persons.
  12. The relationships between physical performance, activity levels and falls in older men.
  13. Association of Thyroid Hormone Therapy With Quality of Life and Thyroid-Related Symptoms in Patients With Subclinical Hypothyroidism: A Systematic Review and Meta-analysis.
  14. The Relation Between Thyroid Function and Anemia: A Pooled Analysis of Individual Participant Data.
  15. Impact of Thyroid Hormone Therapy on Atherosclerosis in the Elderly With Subclinical Hypothyroidism: A Randomized Trial.
  16. Osteoporosis Treatment After Hip Fracture: Bad News and Getting Worse.
  17. Bone Turnover Markers Are Not Associated With Hip Fracture Risk: A Case-Control Study in the Women's Health Initiative.
  18. Initial evaluation of thyroid dysfunction - Are simultaneous TSH and fT4 tests necessary?
  19. Thyroid Dysfunction and Anemia: A Prospective Cohort Study and a Systematic Review.
  20. Low thyroid function is not associated with an accelerated deterioration in renal function.
  21. High-throughput serum proteomics for the identification of protein biomarkers of mortality in older men.
  22. Von Willebrand factor indicates bacterial translocation, inflammation, and procoagulant imbalance and predicts complications independently of portal hypertension severity.
  23. Treatment-Related Changes in Bone Turnover and Fracture Risk Reduction in Clinical Trials of Anti-Resorptive Drugs: A Meta-Regression.
  24. Predicting Vaginal Delivery in Nulliparous Women Undergoing Induction of Labor at Term.
  25. Insights into the bisphosphonate holiday: a preliminary FTIRI study.
  26. Effect of Combination Folic Acid, Vitamin B6 , and Vitamin B12 Supplementation on Fracture Risk in Women: A Randomized, Controlled Trial.
  27. Predictors of change of trabecular bone score (TBS) in older men: results from the Osteoporotic Fractures in Men (MrOS) Study.
  28. High dairy protein intake is associated with greater bone strength parameters at the distal radius and tibia in older men: a cross-sectional study.
  29. Thyroid Function Within the Normal Range, Subclinical Hypothyroidism, and the Risk of Atrial Fibrillation.
  30. Surveying predictors of late-life longitudinal change in daily activity energy expenditure.
  31. Association between subclinical thyroid dysfunction and change in bone mineral density in prospective cohorts.
  32. Thyroid Hormone Therapy for Older Adults with Subclinical Hypothyroidism.
  33. The association between subclinical thyroid dysfunction and dementia: The Health, Aging and Body Composition (Health ABC) Study.
  34. Evaluating Atypical Features of Femur Fractures: How Change in Radiological Criteria Influenced Incidence and Demography of Atypical Femur Fractures in a Community Setting.
  35. Thyroid Function Tests in the Reference Range and Fracture: Individual Participant Analysis of Prospective Cohorts.
  36. Pain, Quality of Life, and Safety Outcomes of Kyphoplasty for Vertebral Compression Fractures: Report of a Task Force of the American Society for Bone and Mineral Research.
  37. Sex Steroid Hormones and Fracture in a Multiethnic Cohort of Women: The Women's Health Initiative Study (WHI).
  38. Association of Trabecular Bone Score (TBS) With Incident Clinical and Radiographic Vertebral Fractures Adjusted for Lumbar Spine BMD in Older Men: A Prospective Cohort Study.
  39. Identification of Hip BMD Loss and Fracture Risk Markers Through Population-Based Serum Proteomics.
  40. Thyroid Hormone Therapy for Older Adults with Subclinical Hypothyroidism.
  41. Effect of Testosterone Treatment on Volumetric Bone Density and Strength in Older Men With Low Testosterone: A Controlled Clinical Trial.
  42. The Association Between Protein Intake by Source and Osteoporotic Fracture in Older Men: A Prospective Cohort Study.
  43. Study protocol; Thyroid hormone Replacement for Untreated older adults with Subclinical hypothyroidism - a randomised placebo controlled Trial (TRUST).
  44. Potential drug-drug and drug-disease interactions in well-functioning community-dwelling older adults.
  45. Change in Bone Mineral Density Is an Indicator of Treatment-Related Antifracture Effect.
  46. Erratum to: Clinical utility of routine laboratory testing to identify possible secondary causes in older men with osteoporosis: the osteoporotic fractures in men (MrOS) study.
  47. Goal-Directed Treatment for Osteoporosis: A Progress Report From the ASBMR-NOF Working Group on Goal-Directed Treatment for Osteoporosis.
  48. Association of Estrogen Metabolism with Breast Cancer Risk in Different Cohorts of Postmenopausal Women.
  49. Lack of Evidence Linking Calcium With or Without Vitamin D Supplementation to Cardiovascular Disease in Generally Healthy Adults: A Clinical Guideline From the National Osteoporosis Foundation and the American Society for Preventive Cardiology.
  50. Subclinical Thyroid Dysfunction and the Risk of Cognitive Decline: a Meta-Analysis of Prospective Cohort Studies.
  51. Thyroid Function Within the Reference Range and the Risk of Stroke: An Individual Participant Data Analysis.
  52. Thyroid Function Variations Within the Reference Range Do Not Affect Quality of Life, Mood, or Cognitive Function in Community-Dwelling Older Men.
  53. Areal and volumetric bone mineral density and risk of multiple types of fracture in older men.
  54. Managing Osteoporosis in Patients on Long-Term Bisphosphonate Treatment: Report of a Task Force of the American Society for Bone and Mineral Research.
  55. Polypharmacy and specific comorbidities in university primary care settings.
  56. Impact of Drug-Drug and Drug-Disease Interactions on Gait Speed in Community-Dwelling Older Adults.
  57. The Association Between Trabecular Bone Score and Lumbar Spine Volumetric BMD Is Attenuated Among Older Men With High Body Mass Index.
  58. The National Osteoporosis Foundation's methods and processes for developing position statements.
  59. Atrial Fibrillation and Declining Physical Performance in Older Adults: The Health, Aging, and Body Composition Study.
  60. Potential Usefulness of BMD and Bone Turnover Monitoring of Zoledronic Acid Therapy Among Women With Osteoporosis: Secondary Analysis of Randomized Controlled Trial Data.
  61. Antidepressant Use and Recurrent Falls in Community-Dwelling Older Adults: Findings From the Health ABC Study.
  62. Risk Factors for Hip Fracture in Older Men: The Osteoporotic Fractures in Men Study (MrOS).
  63. What Proportion of Incident Radiographic Vertebral Fractures in Older Men Is Clinically Diagnosed and Vice Versa: A Prospective Study.
  64. Sleep Disordered Breathing and Risk of Stroke in Older Community-Dwelling Men.
  65. A Multidimensional Risk Score to Predict All-Cause Hospitalization in Community-Dwelling Older Individuals With Obstructive Lung Disease.
  66. Lower Urinary Tract Symptoms and Risk of Nonspine Fractures among Older Community Dwelling U.S. Men.
  67. Association of Opioids with Falls, Fractures, and Physical Performance among Older Men with Persistent Musculoskeletal Pain.
  68. Estrogen Metabolism and Risk of Postmenopausal Endometrial and Ovarian Cancer: the B ~ FIT Cohort.
  69. Managing Osteoporosis in Patients on Long-Term Bisphosphonate Treatment: Report of a Task Force of the American Society for Bone and Mineral Research.
  70. Association between resistin levels and cardiovascular disease events in older adults: The health, aging and body composition study.
  71. Screening Tests for Osteoporosis: Too Few for Some, Too Many for Others.
  72. Vertebral Fractures: Clinical Importance and Management.
  73. Subclinical Thyroid Dysfunction and Frailty Among Older Men.
  74. Prediction of Incident Major Osteoporotic and Hip Fractures by Trabecular Bone Score (TBS) and Prevalent Radiographic Vertebral Fracture in Older Men.
  75. Clinical utility of routine laboratory testing to identify possible secondary causes in older men with osteoporosis: the Osteoporotic Fractures in Men (MrOS) Study.
  76. Dietary Antioxidants and Longitudinal Changes in Lower Urinary Tract Symptoms in Elderly Men: The Osteoporotic Fractures in Men Study.
  77. Effects of TZD Use and Discontinuation on Fracture Rates in ACCORD Bone Study.
  78. Antihypertensive Use and Recurrent Falls in Community-Dwelling Older Adults: Findings From the Health ABC Study.
  79. Degree of Trauma Differs for Major Osteoporotic Fracture Events in Older Men Versus Older Women.
  80. Anticholinergic Use and Recurrent Falls in Community-Dwelling Older Adults: Findings From the Health ABC Study.
  81. Subclinical Thyroid Dysfunction and Depressive Symptoms among the Elderly: A Prospective Cohort Study.
  82. Estrogen Metabolites Are Not Associated with Colorectal Cancer Risk in Postmenopausal Women.
  83. Association Between Hearing Impairment and Risk of Hospitalization in Older Adults.
  84. Glutamate transporter splice variant expression in an enriched pyramidal cell population in schizophrenia.
  85. Hyponatremia and Fractures: Findings From the MrOS Study.
  86. Thyroid function within the normal range and risk of coronary heart disease: an individual participant data analysis of 14 cohorts.
  87. Subclinical thyroid dysfunction and fracture risk: a meta-analysis.
  88. The excess risk of major osteoporotic fractures in hypothyroidism is driven by cumulative hyperthyroid as opposed to hypothyroid time: an observational register-based time-resolved cohort analysis.
  89. Subclinical Hypothyroidism and the Risk of Stroke Events and Fatal Stroke: An Individual Participant Data Analysis.
  90. Dietary sodium content, mortality, and risk for cardiovascular events in older adults: the Health, Aging, and Body Composition (Health ABC) Study.
  91. Predictive ability of heel quantitative ultrasound for incident fractures: an individual-level meta-analysis.
  92. Arterialized venous bicarbonate is associated with lower bone mineral density and an increased rate of bone loss in older men and women.
  93. Statin use and decline in gait speed in community-dwelling older adults.
  94. Objective measures of activity level and mortality in older men.
  95. Gastroprotective agent underuse in high-risk older daily nonsteroidal anti-inflammatory drug users over time.
  96. Effect of bisphosphonate use on risk of postmenopausal breast cancer: results from the randomized clinical trials of alendronate and zoledronic acid.
  97. A model of BMD changes after alendronate discontinuation to guide postalendronate BMD monitoring.
  98. Patient and physician gender concordance in preventive care in university primary care settings.
  99. Subclinical thyroid dysfunction and the risk for fractures: a systematic review and meta-analysis.
  100. Statins and physical activity in older men: the osteoporotic fractures in men study.
  101. Clinically relevant quality measures for risk factor control in primary care: a retrospective cohort study.
  102. Fracture prediction after discontinuation of 4 to 5 years of alendronate therapy: the FLEX study.
  103. The Dilemma of Treating Subclinical Hypothyroidism: Risk that Current Guidelines Do More Harm than Good.
  104. Thyroid antibody status, subclinical hypothyroidism, and the risk of coronary heart disease: an individual participant data analysis.
  105. Fracture risk in diabetic elderly men: the MrOS study.
  106. Multimorbidity and quality of preventive care in Swiss university primary care cohorts.
  107. Association of electrocardiogram abnormalities and incident heart failure events.
  108. High hip fracture risk in men with severe aortic calcification: MrOS study.
  109. Circulating vitamin D, supplement use, and cardiovascular disease risk: the MrOS Sleep Study.
  110. The calcium supplement controversy: now what?
  111. Vertebral augmentation for symptomatic compression fractures is supported by randomized clinical trials--reply.
  112. Calcium supplements and fracture prevention.
  113. Genetic determinants of heel bone properties: genome-wide association meta-analysis and replication in the GEFOS/GENOMOS consortium.
  114. Natural history and risk factors for adjacent vertebral fractures in the fracture intervention trial.
  115. Subclinical thyroid dysfunction and functional capacity among elderly.
  116. Estrogen metabolism and breast cancer risk among postmenopausal women: a case-cohort study within B~FIT.
  117. Understanding and communicating the benefits and risks of denosumab, raloxifene, and teriparatide for the treatment of osteoporosis.
  118. Clinical practice. Calcium supplements and fracture prevention.
  119. Frailty and risk for heart failure in older adults: the health, aging, and body composition study.
  120. Vertebral augmentation vs nonsurgical therapy: improved symptoms, improved survival, or neither?
  121. Epidemiology and long-term clinical and biologic risk factors for pneumonia in community-dwelling older Americans: analysis of three cohorts.
  122. Racial differences in antilipemic use and lipid control in high-risk older adults: post-Medicare Part D.
  123. Changes in cholesterol-lowering medications use over a decade in community-dwelling older adults.
  124. Modifiable risk factors for pneumonia requiring hospitalization of community-dwelling older adults: the Health, Aging, and Body Composition Study.
  125. BMD changes and predictors of increased bone loss in postmenopausal women after a 5-year course of alendronate.
  126. Effects of antiresorptive therapies on glucose metabolism: results from the FIT, HORIZON-PFT, and FREEDOM trials.
  127. Normocalcemic hyperparathyroidism and hypoparathyroidism in two community-based nonreferral populations.
  128. Genetic variation in antioxidant enzymes, cigarette smoking, and longitudinal change in lung function.
  129. Subclinical hypothyroidism and cardiovascular risk: how to end the controversy.
  130. The burden of urinary incontinence and urinary bother among elderly prostate cancer survivors.
  131. A prospective study of thyroid function, bone loss, and fractures in older men: The MrOS study.
  132. Obesity-related hormones and endometrial cancer among postmenopausal women: a nested case-control study within the B~FIT cohort.
  133. Prevalence and correlates of self-reported medication non-adherence among older adults with coronary heart disease, diabetes mellitus, and/or hypertension.
  134. Bisphosphonate therapy for osteoporosis: benefits, risks, and drug holiday.
  135. Mortality associated with diabetes and cardiovascular disease in older women.
  136. 25-hydroxyvitamin D status and change in physical performance and strength in older adults: the Health, Aging, and Body Composition Study.
  137. Change in hip bone mineral density and risk of subsequent fractures in older men.
  138. Antihypertensive drug class use and differential risk of urinary incontinence in community-dwelling older women.
  139. 25-Hydroxyvitamin D, parathyroid hormone, and mortality in black and white older adults: the health ABC study.
  140. Statin use and risk of prostate cancer in the prospective Osteoporotic Fractures in Men (MrOS) Study.
  141. Cigarette smoking exposure and heart failure risk in older adults: the Health, Aging, and Body Composition Study.
  142. Relationship of changes in total hip bone mineral density to vertebral and nonvertebral fracture risk in women with postmenopausal osteoporosis treated with once-yearly zoledronic acid 5 mg: the HORIZON-Pivotal Fracture Trial (PFT).
  143. Subclinical thyroid dysfunction and the risk of heart failure events: an individual participant data analysis from 6 prospective cohorts.
  144. National Bone Health Alliance Bone Turnover Marker Project: current practices and the need for US harmonization, standardization, and common reference ranges.
  145. Cognitive Impairment and Medication Complexity in Community-Living Older Adults: The Health, Aging and Body Composition Study.
  146. Intensive glycemic control is not associated with fractures or falls in the ACCORD randomized trial.
  147. Atypical femoral fracture risk in patients treated with bisphosphonates.
  148. Thyroid function and prevalent and incident metabolic syndrome in older adults: the Health, Ageing and Body Composition Study.
  149. Subclinical hyperthyroidism and the risk of coronary heart disease and mortality.
  150. Continuing bisphosphonate treatment for osteoporosis--for whom and for how long?
  151. Low 25-hydroxyvitamin D predicts the onset of mobility limitation and disability in community-dwelling older adults: the Health ABC Study.
  152. Calciotropic hormones and the risk of hip and nonspine fractures in older adults: the Health ABC Study.
  153. Inflammatory markers and the risk of hip fracture: the Women's Health Initiative.
  154. Association of a Modified Physiologic Index with mortality and incident disability: the Health, Aging, and Body Composition study.
  155. Bone mineral density and fracture risk in older individuals with CKD.
  156. Association of major and minor ECG abnormalities with coronary heart disease events.
  157. Framingham risk score and alternatives for prediction of coronary heart disease in older adults.
  158. Association of intact parathyroid hormone levels with subsequent hip BMD loss: the Osteoporotic Fractures in Men (MrOS) Study.
  159. Clinical use of bone turnover markers to monitor pharmacologic fracture prevention therapy.
  160. Genetic variation in antioxidant enzymes and lung function.
  161. Relationship between bone mineral density changes with denosumab treatment and risk reduction for vertebral and nonvertebral fractures.
  162. Thyroid function and mortality in older men: a prospective study.
  163. Height loss in older women: risk of hip fracture and mortality independent of vertebral fractures.
  164. The potential value of monitoring bone turnover markers among women on alendronate.
  165. Does the use of ACE inhibitors or angiotensin receptor blockers affect bone loss in older men?
  166. Angiotensin-converting enzyme inhibitor and statin use and incident mobility limitation in community-dwelling older adults: the Health, Aging and Body Composition study.
  167. Dietary antioxidants and forced expiratory volume in 1 s decline: the Health, Aging and Body Composition study.
  168. Analgesic use for knee and hip osteoarthritis in community-dwelling elders.
  169. FRAX, falls, and fracture prediction: predicting the future.
  170. Effects of antiresorptive treatment on nonvertebral fracture outcomes.
  171. Serum 25-hydroxyvitamin D and clinical fracture risk in a multiethnic cohort of women: the Women's Health Initiative (WHI).
  172. Hip fracture and increased short-term but not long-term mortality in healthy older women.
  173. ACP Journal Club. Current use of levothyroxine was associated with increased risk for fractures in patients = 70 years of age.
  174. Novel methods to evaluate fracture risk models.
  175. WHO absolute fracture risk models (FRAX): do clinical risk factors improve fracture prediction in older women without osteoporosis?
  176. Obesity increases and physical activity decreases lower urinary tract symptom risk in older men: the Osteoporotic Fractures in Men study.
  177. Adipokines and the risk of fracture in older adults.
  178. Is age-related decline in lean mass and physical function accelerated by obstructive lung disease or smoking?
  179. Official Positions for FRAX® Bone Mineral Density and FRAX® simplification from Joint Official Positions Development Conference of the International Society for Clinical Densitometry and International Osteoporosis Foundation on FRAX®.
  180. Correlates and prevalence of insufficient 25-hydroxyvitamin D status in black and white older adults: the health, aging and body composition study.
  181. Association of BMD and FRAX score with risk of fracture in older adults with type 2 diabetes.
  182. Proton pump inhibitors and risk of fractures: a meta-analysis of 11 international studies.
  183. Renal function and nonvertebral fracture risk in multiethnic women: the Women's Health Initiative (WHI).
  184. Effects of body composition and adipose tissue distribution on respiratory function in elderly men and women: the health, aging, and body composition study.
  185. European ancestry and resting metabolic rate in older African Americans.
  186. Lung function and risk for heart failure among older adults: the Health ABC Study.
  187. The relationship between bisphosphonate adherence and fracture: is it the behavior or the medication? Results from the placebo arm of the fracture intervention trial.
  188. Mortality risk in older men associated with changes in weight, lean mass, and fat mass.
  189. Discontinuation of odanacatib and other osteoporosis treatments: here today and gone tomorrow?
  190. Bone strength measured by peripheral quantitative computed tomography and the risk of nonvertebral fractures: the osteoporotic fractures in men (MrOS) study.
  191. Bisphosphonate use and atypical femoral fractures: getting down to brass tacks.
  192. Subclinical thyroid dysfunction and incident hip fracture in older adults.
  193. Consistency of bone turnover marker and calcium responses to parathyroid hormone (1-84) therapy in postmenopausal osteoporosis.
  194. The influence of pre-existing diabetes mellitus on the host immune response and outcome of pneumonia: analysis of two multicentre cohort studies.
  195. Subclinical hypothyroidism and the risk of coronary heart disease and mortality.
  196. Arterial stiffness and gait speed in older adults with and without peripheral arterial disease.
  197. The effect of medication use on urinary incontinence in community-dwelling elderly women.
  198. Serum albumin concentration and heart failure risk The Health, Aging, and Body Composition Study.
  199. Serum 25-hydroxyvitamin D, parathyroid hormone, and mortality in older men.
  200. Estimates of the proportion of older white men who would be recommended for pharmacologic treatment by the new US National Osteoporosis Foundation guidelines.
  201. Sex steroid hormones in older men: longitudinal associations with 4.5-year change in hip bone mineral density--the osteoporotic fractures in men study.
  202. Inflammatory markers and incident heart failure risk in older adults: the Health ABC (Health, Aging, and Body Composition) study.
  203. Sex hormones and the risk of incident prostate cancer.
  204. Accuracy of self-reported diagnosis of hip replacement.
  205. Efficacy of continued alendronate for fractures in women with and without prevalent vertebral fracture: the FLEX trial.
  206. Serum 25-OH vitamin D levels and risk of developing prostate cancer in older men.
  207. Filtering FRAX.
  208. Progression of lower urinary tract symptoms in older men: a community based study.
  209. Bisphosphonates and fractures of the subtrochanteric or diaphyseal femur.
  210. Epidemiology of rib fractures in older men: Osteoporotic Fractures in Men (MrOS) prospective cohort study.
  211. Computed tomographic measurements of thigh muscle cross-sectional area and attenuation coefficient predict hip fracture: the health, aging, and body composition study.
  212. Inverse association between serum 25(OH) vitamin D levels and non-melanoma skin cancer in elderly men.
  213. Predictors of mortality in elderly subjects with obstructive airway disease: the PILE score.
  214. Serum 25-hydroxyvitamin D and the risk of hip and nonspine fractures in older men.
  215. Markers of atherosclerosis and inflammation for prediction of coronary heart disease in older adults.
  216. Association of osteocalcin and abdominal aortic calcification in older women: the study of osteoporotic fractures.
  217. Physical performance and subsequent disability and survival in older adults with malignancy: results from the health, aging and body composition study.
  218. The value of routine BMD monitoring after starting bisphosphonate treatment.
  219. Biochemical markers of bone turnover, hip bone loss, and fracture in older men: the MrOS study.
  220. Drug burden index score and functional decline in older people.
  221. Subclinical hypothyroidism and functional mobility in older adults.
  222. Ceftobiprole is superior to vancomycin, daptomycin, and linezolid for treatment of experimental endocarditis in rabbits caused by methicillin-resistant Staphylococcus aureus.
  223. Assessing fracture risk and effects of osteoporosis drugs: bone mineral density and beyond.
  224. Effect of adherence on lifetime fractures in osteoporotic women treated with daily and weekly bisphosphonates.
  225. Central nervous system medication use and incident mobility limitation in community elders: the Health, Aging, and Body Composition study.
  226. Activity energy expenditure and change in body composition in late life.
  227. Value of routine monitoring of bone mineral density after starting bisphosphonate treatment: secondary analysis of trial data.
  228. Laboratory reproducibility of biochemical markers of bone turnover in clinical practice.
  229. Baseline serum estradiol and fracture reduction during treatment with hormone therapy: the Women's Health Initiative randomized trial.
  230. Bone: Does TSH concentration influence skeletal health?
  231. Risk factors for severity and type of the hip fracture.
  232. Glycemic status and incident heart failure in elderly without history of diabetes mellitus: the health, aging, and body composition study.
  233. Activity energy expenditure and mobility limitation in older adults: differential associations by sex.
  234. Pentosidine and increased fracture risk in older adults with type 2 diabetes.
  235. Epidemiology of incident heart failure in a contemporary elderly cohort: the health, aging, and body composition study.
  236. Estimates of the proportion of older white women who would be recommended for pharmacologic treatment by the new U.S. National Osteoporosis Foundation Guidelines.
  237. Fetuin-A and BMD in older persons: the Health Aging and Body Composition (Health ABC) study.
  238. Self-reported sleep and nap habits and risk of mortality in a large cohort of older women.
  239. Number and dosage of central nervous system medications on recurrent falls in community elders: the Health, Aging and Body Composition study.
  240. Added value of physical performance measures in predicting adverse health-related events: results from the Health, Aging And Body Composition Study.
  241. Effect of central nervous system medication use on decline in cognition in community-dwelling older adults: findings from the Health, Aging And Body Composition Study.
  242. Homocysteine levels and risk of hip fracture in postmenopausal women.
  243. The association of bone mineral density with prostate cancer risk in the Osteoporotic Fractures in Men (MrOS) Study.
  244. Association of the ACTN3 genotype and physical functioning with age in older adults.
  245. Randomized trial reporting in general endocrine journals: the good, the bad, and the ugly.
  246. Subclinical thyroid dysfunction, cardiac function, and the risk of heart failure. The Cardiovascular Health study.
  247. Acid-suppressive medications and risk of bone loss and fracture in older adults.
  248. Effects of PTH and alendronate on type I collagen isomerization in postmenopausal women with osteoporosis: the PaTH study.
  249. Biochemical markers of bone turnover and their association with bone marrow lesions.
  250. Serum 25-hydroxyvitamin D concentrations and risk for hip fractures.
  251. Optimal thresholds, linear or nonlinear relationships of fracture risk reduction with therapy.
  252. Cystatin-C, renal function, and incidence of hip fracture in postmenopausal women.
  253. Incident heart failure prediction in the elderly: the health ABC heart failure score.
  254. Single-point assessment of warfarin use and risk of osteoporosis in elderly men.
  255. Meta-analysis: subclinical thyroid dysfunction and the risk for coronary heart disease and mortality.
  256. Does a history of non-vertebral fracture identify women without osteoporosis for treatment?
  257. Persistent hot flushes in older postmenopausal women.
  258. The metabolic syndrome is associated with circulating adipokines in older adults across a wide range of adiposity.
  259. Associations of serum sex hormone-binding globulin and sex hormone concentrations with hip fracture risk in postmenopausal women.
  260. The effect of alendronate on progression of spinal osteophytes and disc-space narrowing.
  261. Quantitative ultrasound in the management of osteoporosis: the 2007 ISCD Official Positions.
  262. High-trauma fractures and low bone mineral density in older women and men.
  263. Association between subclinical hypothyroidism and coronary heart disease in 2006.
  264. Rate and circumstances of clinical vertebral fractures in older men.
  265. Change in serum measurements of cartilage oligomeric matrix protein and association with the development and worsening of radiographic hip osteoarthritis.
  266. [Osteochondral marker proteins in the quantitative evaluation of matrix-based autologous chondrocyte transplantation CaRes].
  267. Cost-effectiveness of bone densitometry followed by treatment of osteoporosis in older men.
  268. Body mass index and mortality among older breast cancer survivors in the Study of Osteoporotic Fractures.
  269. A drug burden index to define the functional burden of medications in older people.
  270. Polymorphisms of angiotensinogen and angiotensin-converting enzyme associated with lower extremity arterial disease in the Health, Aging and Body Composition study.
  271. Alendronate treatment in women with normal to severely impaired renal function: an analysis of the fracture intervention trial.
  272. Hot flushes, bone mineral density, and fractures in older postmenopausal women.
  273. Influence of comorbid conditions on long-term mortality after pneumonia in older people.
  274. Thyroid hormone use, hyperthyroidism and mortality in older women.
  275. Peak expiratory flow is not a quality indicator for spirometry: peak expiratory flow variability and FEV1 are poorly correlated in an elderly population.
  276. Association between aortic calcification and total and cardiovascular mortality in older women.
  277. Racial variation in the relationship of anemia with mortality and mobility disability among older adults.
  278. Quantitative ultrasound predicts hip and non-spine fracture in men: the MrOS study.
  279. Evaluating the value of repeat bone mineral density measurement and prediction of fractures in older women: the study of osteoporotic fractures.
  280. Genetic markers for ancestry are correlated with body composition traits in older African Americans.
  281. Cartilage markers and their association with cartilage loss on magnetic resonance imaging in knee osteoarthritis: the Boston Osteoarthritis Knee Study.
  282. Effects of continuing or stopping alendronate after 5 years of treatment: the Fracture Intervention Trial Long-term Extension (FLEX): a randomized trial.
  283. Risk factors for mortality in middle-aged women.
  284. Review: human parathyroid hormone reduces fractures and increases bone mineral density in severe osteoporosis.
  285. Prevalence, severity, and health correlates of lower urinary tract symptoms among older men: the MrOS study.
  286. Potential for bone turnover markers to cost-effectively identify and select post-menopausal osteopenic women at high risk of fracture for bisphosphonate therapy.
  287. Case-only analysis of treatment-covariate interactions in clinical trials.
  288. Volumetric and areal bone mineral density measures are associated with cardiovascular disease in older men and women: the health, aging, and body composition study.
  289. Self-reported sleep and nap habits and risk of falls and fractures in older women: the study of osteoporotic fractures.
  290. Urinary pentosidine does not predict cartilage loss among subjects with symptomatic knee OA: the BOKS Study.
  291. Daily activity energy expenditure and mortality among older adults.
  292. Subclinical hypothyroidism and the risk of coronary heart disease: a meta-analysis.
  293. Impaired muscle strength is associated with fractures in hemodialysis patients.
  294. Classification of osteoarthritis biomarkers: a proposed approach.
  295. Correlates of use of antifracture therapy in older women with low bone mineral density.
  296. Statin use and breast cancer: prospective results from the Women's Health Initiative.
  297. Cortical pQCT measures are associated with fractures in dialysis patients.
  298. Therapy modifications in response to poorly controlled hypertension, dyslipidemia, and diabetes mellitus.
  299. Metabolic syndrome and the risk of cardiovascular disease in older adults.
  300. Short-term changes in bone turnover markers and bone mineral density response to parathyroid hormone in postmenopausal women with osteoporosis.
  301. Subclinical hypothyroidism and the risk of heart failure, other cardiovascular events, and death.
  302. Inflammatory markers are associated with ventilatory limitation and muscle dysfunction in obstructive lung disease in well functioning elderly subjects.
  303. Aspirin use for the primary prevention of coronary heart disease in older adults.
  304. Correlates and prevalence of prostatitis in a large community-based cohort of older men.
  305. Pretreatment levels of bone turnover and the antifracture efficacy of alendronate: the fracture intervention trial.
  306. Circulating levels of inflammatory markers and cancer risk in the health aging and body composition cohort.
  307. Prognostic value of usual gait speed in well-functioning older people--results from the Health, Aging and Body Composition Study.
  308. Nontraumatic fracture risk with diabetes mellitus and impaired fasting glucose in older white and black adults: the health, aging, and body composition study.
  309. Hyperhomocysteinaemia and aortic calcification are associated with fractures in patients on haemodialysis.
  310. Elevated aortic pulse wave velocity, a marker of arterial stiffness, predicts cardiovascular events in well-functioning older adults.
  311. Economic comparison of diagnostic approaches for evaluating osteoporosis in older women.
  312. Factors associated with the lumbar spine and proximal femur bone mineral density in older men.
  313. Parathyroid hormone and teriparatide for the treatment of osteoporosis: a review of the evidence and suggested guidelines for its use.
  314. Aspirin for the primary prevention of cardiovascular disease: a comprehensive review.
  315. Assessment of vertebral fracture using densitometric morphometry.
  316. beta-Blocker use, BMD, and fractures in the study of osteoporotic fractures.
  317. Combination and sequential therapy with PTH and bisphosphonates.
  318. Risk factors for a first-incident radiographic vertebral fracture in women > or = 65 years of age: the study of osteoporotic fractures.
  319. Assessing the risk/benefit profile before recommending aspirin for the primary prevention of cardiovascular events.
  320. Clinical utility of laboratory testing in women with osteoporosis.
  321. Effect of alendronate on bone mineral density and biochemical markers of bone turnover in type 2 diabetic women: the fracture intervention trial.
  322. Change in bone turnover and hip, non-spine, and vertebral fracture in alendronate-treated women: the fracture intervention trial.
  323. Randomized trial of effect of alendronate continuation versus discontinuation in women with low BMD: results from the Fracture Intervention Trial long-term extension.
  324. Diabetes is associated independently of body composition with BMD and bone volume in older white and black men and women: The Health, Aging, and Body Composition Study.
  325. Low serum vitamin B-12 levels are associated with increased hip bone loss in older women: a prospective study.
  326. Energy requirements in the eighth decade of life.
  327. Use of statins and fracture: results of 4 prospective studies and cumulative meta-analysis of observational studies and controlled trials.
  328. Should age influence the choice of quantitative bone assessment technique in elderly women? The EPIDOS study.
  329. [Amniotic membrane transplantation improves experimental herpetic keratitis. Modulation of matrix metalloproteinase-9].
  330. Water turnover in 458 American adults 40-79 yr of age.
  331. Estrogen metabolites and the risk of breast cancer in older women.
  332. Association between bone mineral density and the use of nonsteroidal anti-inflammatory drugs and aspirin: impact of cyclooxygenase selectivity.
  333. Lipid-lowering drug use and breast cancer in older women: a prospective study.
  334. Statin use, clinical fracture, and bone density in postmenopausal women: results from the Women's Health Initiative Observational Study.
  335. Relationship of changes in physical activity and mortality among older women.
  336. HMG CoA reductase inhibitors and the skeleton: a comprehensive review.
  337. Nulliparity and fracture risk in older women: the study of osteoporotic fractures.
  338. Central nervous system active medications and risk for fractures in older women.
  339. Incidence and risk factors for a second hip fracture in elderly women. The Study of Osteoporotic Fractures.
  340. Osteoporosis and fractures in postmenopausal women using estrogen.
  341. Central nervous system-active medications and risk for falls in older women.
  342. Oral bisphosphonates and upper gastrointestinal tract problems: what is the evidence?
  343. Quality indicators for management of osteoporosis.
  344. Quantitative ultrasound and mortality: a prospective study.
  345. Association between thyroid dysfunction and total cholesterol level in an older biracial population: the health, aging and body composition study.
  346. Influence of delayed isotopic equilibration in urine on the accuracy of the (2)H(2)(18)O method in the elderly.
  347. Changes in biochemical markers of bone turnover in women treated with raloxifene: influence of regression to the mean.
  348. Timing of estrogen replacement therapy for optimal osteoporosis prevention.
  349. Type 2 diabetes in older well-functioning people: who is undiagnosed? Data from the Health, Aging, and Body Composition study.
  350. Measuring fitness in healthy older adults: the Health ABC Long Distance Corridor Walk.
  351. Association between endogenous hormones and sex hormone-binding globulin and bone turnover in older women: study of osteoporotic fractures.
  352. Influence of smoking on the antiosteoporotic efficacy of raloxifene.
  353. Airflow limitation is underrecognized in well-functioning older people.
  354. Induction of cytochrome P450 2B1 by pyrethroids in primary rat hepatocyte cultures.
  355. Race and sex effects on the association between muscle strength, soft tissue, and bone mineral density in healthy elders: the Health, Aging, and Body Composition Study.
  356. Bone mass and breast cancer risk in older women: differences by stage at diagnosis.
  357. Isolated cervical juvenile xanthogranuloma in childhood.
  358. Repression of phenobarbital-dependent CYP2B1 mRNA induction by reactive oxygen species in primary rat hepatocyte cultures.
  359. Risk for fracture in women with low serum levels of thyroid-stimulating hormone.
  360. Bone mineral density and endogenous hormones and risk of breast cancer in postmenopausal women (United States).
  361. Fracture risk reduction with alendronate in women with osteoporosis: the Fracture Intervention Trial. FIT Research Group.
  362. Alendronate and nonsteroidal anti-inflammatory drug interaction safety is not established: a reply.
  363. An antigenic threshold for maintaining human immunodeficiency virus type 1-specific cytotoxic T lymphocytes.
  364. Osteoporotic fractures: ignorance is bliss?
  365. Do statins prevent both cardiovascular disease and fracture?
  366. Upper gastrointestinal tract safety profile of alendronate: the fracture intervention trial.
  367. Clinical use of biochemical markers of bone remodeling: current status and future directions.
  368. Biochemical markers of bone turnover and prediction of hip bone loss in older women: the study of osteoporotic fractures.
  369. Hip fractures attributable to corticosteroid use. Study of Osteoporotic Fractures Group.
  370. Clinical significance of sleep-related breathing disorders in patients with implantable cardioverter defibrillators.
  371. Intermittent use of nitrates increases bone mineral density: the study of osteoporotic fractures.
  372. Activity of secreted Kunitz domain 1 variants of tissue factor pathway inhibitor.
  373. [Clinical significance of sleep apnea disorders after implantation of a cardioverter-defibrillator in patients with cardiac disease and sustained ventricular tachyarrhythmia].
  374. Endogenous hormones and the risk of hip and vertebral fractures among older women. Study of Osteoporotic Fractures Research Group.
  375. Physical activity and osteoporotic fracture risk in older women. Study of Osteoporotic Fractures Research Group.
  376. Associations between low levels of serum estradiol, bone density, and fractures among elderly women: the study of osteoporotic fractures.
  377. Genetic variation in alpha 2HS-glycoprotein is related to calcaneal broadband ultrasound attenuation in older women.
  378. Hormonal predictors of bone loss in elderly women: a prospective study. The Study of Osteoporotic Fractures Research Group.
  379. Thyroid functions and serum lipids in older women: a population-based study.
  380. Warfarin use and risk for osteoporosis in elderly women. Study of Osteoporotic Fractures Research Group.
  381. Is alendronate clinically gastrotoxic? Re: Graham et al. primary amino-bisphosphonates: a new class of gastrotoxic drugs--comparison of alendronate and aspirin.
  382. Treatment with alendronate prevents fractures in women at highest risk: results from the Fracture Intervention Trial.
  383. Low thyrotropin levels are not associated with bone loss in older women: a prospective study.
  384. Aspirin and nonsteroidal antiinflammatory drug use in elderly women: effects on a marker of bone resorption. The Study of Osteoporotic Fractures Research Group.
  385. Broadband ultrasound attenuation predicts fractures strongly and independently of densitometry in older women. A prospective study. Study of Osteoporotic Fractures Research Group.
  386. Calcaneal ultrasound attenuation in older African-American and Caucasian-American women.
  387. Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture Intervention Trial Research Group.
  388. Sensitive thyrotropin and free thyroxine testing in outpatients. Are both necessary?
  389. Osteoporosis: association of recent fractures with quantitative US findings.
  390. Thyroid hormone use and fractures.
  391. Axial bone mass in older women. Study of Osteoporotic Fractures Research Group.
  392. Aspirin and NSAID use in older women: effect on bone mineral density and fracture risk. Study of Osteoporotic Fractures Research Group.
  393. Quantitative ultrasound and vertebral fracture in postmenopausal women. Fracture Intervention Trial Research Group.
  394. Detection and differential display of expressed genes by DDRT-PCR.
  395. Factors associated with appendicular bone mass in older women. The Study of Osteoporotic Fractures Research Group.
  396. Ultrasound surveillance to detect postoperative venous thrombosis.
  397. Evaluation of hematuria in adults.